ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

• ClinicalTrials.gov Identifier: NCT05507203
• Recruitment Status: Recruiting
• First Posted: August 18, 2022
• Last Update Posted: May 20, 2024
• Sponsor: Abivax S.A.
• Information provided by (Responsible Party): Abivax S.A.

Tracking Information

• First Submitted Date: August 17, 2022
• First Posted Date: August 18, 2022
• Last Update Posted Date: May 20, 2024
• Actual Study Start Date: October 10, 2022
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: September 1, 2022)

Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8 [ Time Frame: 8 weeks ]

To compare the efficacy of ABX464 versus placebo on clinical remission

Original Primary Outcome Measures (submitted: August 17, 2022)

To compare the efficacy of ABX464 versus placebo on clinical remission [ Time Frame: 8 weeks ]

Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8

Current Secondary Outcome Measures (submitted: May 16, 2024)

• Proportion of subjects who achieve endoscopic improvement at week 8 [ Time Frame: 8 weeks ]
  To compare the efficacy of ABX464 versus placebo on endoscopic improvement
• Proportion of subjects who achieve clinical response per MMS at week 8 [ Time Frame: 8 weeks ]
  To compare the efficacy of ABX464 versus placebo on clinical response as per MMS
• Proportion of subjects with symptomatic remission at week 8 [ Time Frame: 8 weeks ]
  To compare the efficacy of ABX464 versus placebo on symptomatic remission
• Proportion of subjects with HEMI per Geboes at week 8 [ Time Frame: 8 weeks ]
  To compare the efficacy of ABX464 versus placebo on histologic-endoscopic mucosal

Original Secondary Outcome Measures (submitted: August 17, 2022)

• To compare the efficacy of ABX464 versus placebo on endoscopic improvement [ Time Frame: 8 weeks ]
  Proportion of subjects who achieve endoscopic improvement at week 8
• To compare the efficacy of ABX464 versus placebo on clinical response as per MMS [ Time Frame: 8 weeks ]
  Proportion of subjects who achieve clinical response per MMS at week 8
• To compare the efficacy of ABX464 versus placebo on symptomatic remission [ Time Frame: 8 weeks ]
  Proportion of subjects with symptomatic remission at week 8
• To compare the efficacy of ABX464 versus placebo on histologic-endoscopic mucosal improvement (HEMI). [ Time Frame: 8 weeks ]
  Proportion of subjects with HEMI per Geboes at week 8

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
• Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
• Brief Summary: This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Care Provider, Investigator); Primary Purpose: Treatment
• Condition: Ulcerative Colitis

Intervention

• Drug: ABX464
  Administered once daily in the morning with food
  Other Name: Obefazimod
• Drug: Placebo
  Administered once daily in the morning with food

Study Arms

• Experimental: ABX464 50mg
  Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
  Intervention: Drug: ABX464
• Experimental: ABX464 25mg
  Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
  Intervention: Drug: ABX464
• Placebo Comparator: Placebo
  Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks
  Intervention: Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: August 17, 2022): 612
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: February 2025
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority. If these approvals have not been granted, only subjects ≥ 18 years old will be enrolled. To be eligible, adolescent subjects must weight ≥ 40 kg and meet the definition of Tanner Stage 5 at the screening visit.
• Subjects must understand, sign and date the written voluntary informed consent form at the visit prior to any protocol-specific procedures. For under-aged subjects, national requirements regarding consent should also be met.
• Documented diagnosis of UC confirmed by endoscopy and histology. Should endoscopy/histology results not be available at screening, results from endoscopies or biopsies taken at screening may be used.
• Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).
• Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).
• Women of childbearing potential (WOCBP) subjects and male subjects with WOCBP partner must agree to comply with the contraception requirements described in the protocol.
• Subjects able and willing to comply with study visits and procedures as per protocol.
• Subjects should be affiliated to a health insurance policy whenever required by a participating country or state.

Exclusion Criteria:

• Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading.
• Subjects with primary sclerosing cholangitis or autoimmune hepatitis.
• Subjects who have failed on 5-ASA or sulfasalazine therapy only.
• Subjects with CD or presence or history of fistula, indeterminate colitis, infectious/ischemic colitis or microscopic colitis (lymphocytic and collagenous colitis).
• History or current evidence of toxic megacolon, fulminant colitis, bowel perforation.
• History of colonic cancer or colonic low grade or high grade dysplasia adenomatous polyps, and/or at the screening endoscopy, evidence of colonic cancer or evidence of low grade or high grade dysplasia adenomatous polyps (fully removed or not).
• Recent or planned bowel surgery or history of proctocolectomy or partial colectomy or current stoma.
• Subjects on antidiarrheals including those working on motility (e.g., loperamide, diphenoxylate with atropine, etc.).
• Subjects on probiotics (e.g., Culturelle® [Lactobacillus GG, i-Health, Inc.], Saccharomyces boulardii).
• Subjects who do not meet the washout period requirements prior to the screening endoscopy

• Subjects with the following hematological and biochemical laboratory parameters obtained during the screening period:

  • Hemoglobin ≤ 8.0 g dL-1
  • Absolute neutrophil count < 750 mm-3
  • Platelets < 100,000 mm-3
  • Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)
  • Total serum bilirubin > 1.5 x ULN
  • Alkaline phosphatase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2 x ULN

• Subjects with the following conditions (infection):

  • Subjects with chronic or recurrent grade 3 or grade 4 infection within the last 2 months prior to screening or a history of opportunistic infection while not on immunosuppressive therapy.
  • Herpes zoster reactivation within the last 2 months prior to screening.
  • Subjects with active infection at screening or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 1 month of screening or during screening. Fungal infection of nail beds is allowed.
  • Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridium difficile toxin at screening. If C. difficile is positive, subject may be treated and retested ≥ 2 weeks after completing treatment.
  • Subjects with HIV infection.
  • Subjects having acute or chronic hepatitis B infection at screening (positive for hepatitis B surface antigen [HbsAg], or negative for HbsAg and positive for anti-hepatitis B core antibody in conjunction with detectable HBV DNA, or detectable HBV DNA).
  • Subjects having acute or chronic hepatitis C infection at screening as defined by positive for hepatitis C antibody (subjects successfully treated and without recurrence ≥ 1 year with no detectable HCV RNA [assessed centrally] are eligible).
  • Active tuberculosis (TB) or untreated latent TB are ruled out. For subjects with positive or intermediate QuantiFERON test see study protocol.
• Subjects with an uncontrolled ischemic heart disease and/or a history of congestive heart failure with New York Heart Association (NYHA) class 3 or 4 symptoms.
• Subjects with a family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval [Fridericia or Bazett correction] >450 milliseconds for male and > 460 milliseconds for female).
• Subjects with a history of torsade de pointe (TdP).
• Acute or chronic of clinically relevant pulmonary, hepatic, pancreatic or renal functional abnormality, encephalopathy, neuropathy or unstable central nervous system pathology such as seizure disorder, or any other clinically significant medical problems as determined by physical examination and/or laboratory screening tests and/or medical history (note: treated autoimmune hypothyroidy and autoimmune diabetes are allowed).
• Acute or chronic pancreatitis, determined by amylase and/or lipase elevations ≥ 3 ULN at screening and abnormal imaging results (CT, MRI, or ultrasound) during the screening period.
• History or active malignancy including non-melanoma skin cancer (subjects with a 5-year disease free survival are eligible).
• Serious illness requiring hospitalization within 4 weeks prior to screening (except UC flare).
• Subjects previously treated with ABX464.
• Subjects with a known hypersensitivity to the active substance or to any of the excipients.
• WOCBP subject who is pregnant or breast-feeding at screening, or intends to become pregnant during the study, or male subject with WOCBP partner who intends to be pregnant during the study.
• Illicit drug or alcohol abuse or dependence.
• Subjects who received live vaccine within 3 months prior to screening and/or who's planning to receive such a vaccine during the study duration.
• Use of any investigational or non-registered product within 3 months or within 5 half-lives preceding baseline, whichever is longer, and during the study.
• Subjects committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
• Any condition, which in the opinion of the investigator, could compromise the subject's safety or adherence to the study protocol.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 16 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Sharon Skare, CPhil; +33153830961; sharon.skare@abivax.com

• Listed Location Countries: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Italy, Korea, Republic of, Netherlands, Poland, Portugal, Spain, Switzerland, Turkey, United Kingdom, United States

Administrative Information

• NCT Number: NCT05507203
• Other Study ID Numbers: ABX464-105
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Abivax S.A.
• Original Responsible Party: Same as current
• Current Study Sponsor: Abivax S.A.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Abivax S.A.
• Verification Date: April 2024